cryopyrin

Ilaris treats cryopyrin-associated periodic syndrome, or CAPS, a rare, inherited disorder caused by a mutation in a single gene.

FDA Approves a Novel Novartis Drug 2009

The concept of targeting the IL-1 pathway in some inflammatory diseases has been clinically validated by three FDA-approved therapies, one for rheumatoid arthritis, and two for cryopyrin-associated periodic syndromes (CAPS).

News 2010

Background The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1.

New England Journal of Medicine Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner 2009

When cryopyrin latches onto a foreign molecule that is part of an invading virus or bacterium, it activates other components of the innate immune response.

unknown title 2009

Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1 in patients with cryopyrin-associated periodic syndromes.

Presseportal 2009

Cryopyrin regulates the release of interleukin-1, an important mediator of fever and systemic inflammation during the body's innate immune response, and alterations in cryopyrin lead to over-production of Il-1.

RxPG News : Latest Medical, Healthcare and Research News 2009

PhD, both of Immunology, and their colleagues explored further the in vivo role of the cryopyrin/caspase-1 machinery during influenza virus infection.

unknown title 2009

The researchers discovered clues to how cryopyrin detects that the influenza virus has invaded an immune cell.

unknown title 2009

In 2008, the FDA approved the second IL-1 drug, rilonacept, for cryopyrin-associated periodic syndromes (CAPS), providing additional regulatory support for the development of IL-1 therapeutics.

News 2009

The findings about the cryopyrin machinery also have implications beyond influenza.

unknown title 2009